Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
36 hedge funds and large institutions have $1.56M invested in Carisma Therapeutics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 37 → 36 (-1)
3.82% less ownership
Funds ownership: 13.36% → 9.53% (-3.8%)
10% less capital invested
Capital invested by funds: $1.73M → $1.56M (-$171K)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$40.4K |
| 2 |
Renaissance Technologies
New York
|
+$20.2K |
| 3 |
GS
GTS Securities
New York
|
+$13.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.09K |
| 5 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$4.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$280K |
| 2 |
Barclays
London,
United Kingdom
|
-$147K |
| 3 |
Universal-Beteiligungs- und Servicegesellschaft
Frankfurt Am Main,
Germany
|
-$62K |
| 4 |
BlackRock
New York
|
-$18.8K |
| 5 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
-$6.88K |
CARM Hedge Fund Activity: Q2 2025 in Review
36 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2025, worth a combined $1.56M — down 9.9% from $1.73M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CARM and 5 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 4 added.
The largest buyer was Jane Street, opening a new position worth an estimated $40.4K. The largest seller was Vanguard Group, cutting an estimated $280K.
- 36 institutional investors held Carisma Therapeutics (CARM) as of Q2 2025, down from 37 in Q1 2025.
- Funds reported $1.56M of Carisma Therapeutics stock for Q2 2025, down 9.9% quarter-over-quarter.
- 5 funds opened new Carisma Therapeutics positions in Q2 2025 and 6 closed out, a net change of -1 holder.
- The largest Carisma Therapeutics buyer in Q2 2025 was Jane Street, an estimated $40.4K added.
- The largest Carisma Therapeutics seller in Q2 2025 was Vanguard Group, an estimated $280K sold.
Based on aggregated 13F filings for Q2 2025.